• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    (CSE:QNTM)

    5.600 UNCHANGED
    Streaming Delayed Price Updated: 12:36 PM EDT, Jun 25, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 5,625
    Open 5.600
    Bid (Size) 5.520 (200)
    Ask (Size) 5.600 (600)
    Prev. Close 5.600
    Today's Range 5.600 - 5.700
    52wk Range 2.850 - 43.00
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Featured in BioMedWire Editorial on Multiple Sclerosis Treatment
    Via Investor Brand Network
    News headline image
    Quantum BioPharma Ltd. (NASDAQ: QNTM) Advancing Innovative, First-in-Class, Patented MS Therapy
    From Quantum BioPharma Ltd.
    Via GlobeNewswire

    Performance

    YTD
    -42.9%
    -42.9%
    1 Month
    -42.9%
    -42.9%
    3 Month
    +4.3%
    +4.3%
    6 Month
    -49.6%
    -49.6%
    1 Year
    -83.0%
    -83.0%

    More News

    Read More
    The Quest to Repair What Multiple Sclerosis Takes Away
    Via Investor Brand Network
    Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Is ‘One to Watch’
    Via Investor Brand Network
    InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Lucid-MS Toward Phase 2 Trials for Multiple Sclerosis
    Via Investor Brand Network
    News headline image
    The Quest to Repair What Multiple Sclerosis Takes Away
    From BioMedWire
    Via GlobeNewswire
    BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Featured in BioMedWire Editorial on Lucid-MS Program
    Via Investor Brand Network
    News headline image
    Quantum BioPharma Ltd. (NASDAQ: QNTM) Developing Patented, First-in-Class MS Treatment That Offers Different Approach
    From Quantum BioPharma Ltd.
    Via GlobeNewswire
    MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Novel Multiple Sclerosis Therapy Toward Phase 2 Trials
    Via Investor Brand Network
    Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis
    Via Investor Brand Network
    News headline image
    Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis
    From BioMedWire
    Via GlobeNewswire
    Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Proprietary Therapy for Multiple Sclerosis Treatment
    Via Investor Brand Network
    Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Builds Diversified Pipeline Across Neurological and Wellness Markets
    Via Investor Brand Network
    InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Engages Stocks.news for Investor Relations Services
    Via Investor Brand Network
    MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Highlights Lucid-MS and unbuzzd(TM) Growth Opportunities on BioMedWire Podcast
    Via Investor Brand Network
    BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Highlights Lucid-MS and unbuzzd(TM) Growth Opportunities on BioMedWire Podcast
    Via Investor Brand Network
    News headline image
    Quantum BioPharma Engages Stocks.news For Investor Relations, Marketing Services And Lead Generation Campaigns
    From Quantum BioPharma
    Via GlobeNewswire
    BioMedNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Reports Midpoint Enrollment Milestone in Multiple Sclerosis Imaging Study
    Via Investor Brand Network
    News headline image
    Quantum BioPharma Reaches Key Midpoint Milestone in Groundbreaking Imaging Study with Massachusetts General Hospital
    From Quantum BioPharma
    Via GlobeNewswire
    News headline image
    Quantum Reports Strengthened Liquidity, Reduced Cash Burn, and Disciplined Cost Management in First Quarter 2026
    From Quantum BioPharma
    Via GlobeNewswire
    News headline image
    Quantum BioPharma Licensee Unbuzzd Wellness Inc. Appoints Richard Buzbuzian as CEO to Lead Nationwide Commercialization of Innovative, Clinically Validated Hangover Remedy and Alcohol Metabolism Accelerant
    From Quantum BioPharma
    Via GlobeNewswire
    News headline image
    Quantum BioPharma Wins Significant Court Challenge in USD $700,000,000 Claim as Defendants Joint Motion to Dismiss Lawsuit Alleging Market Manipulation by CIBC World Markets and RBC Dominion Securities is Denied
    From Quantum BioPharma
    Via GlobeNewswire
    News headline image
    Quantum BioPharma Submits Investigational New Drug (IND) Application to United States Food and Drug Administration (FDA) for Lucid-MS Phase Two Clinical Trial in Multiple Sclerosis
    From Quantum BioPharma
    Via GlobeNewswire
    News headline image
    Quantum BioPharma Signs Binding Letter Of Intent With Allucent To Conduct Phase 2 Clinical Trial In Multiple Sclerosis
    From Quantum BioPharma
    Via GlobeNewswire
    News headline image
    Quantum Biopharma’s 2025 Audited Year End Financial Results Maintain ‘No Going Concern’ Status
    From Quantum BioPharma
    Via GlobeNewswire

    Frequently Asked Questions

    Is QNTM publicly traded?
    Yes, QNTM is publicly traded.
    What exchange does QNTM trade on?
    QNTM trades on the Canadian Securities Exchange
    What is the ticker symbol for QNTM?
    The ticker symbol for QNTM is QNTM on the Canadian Securities Exchange
    What is the current price of QNTM?
    The current price of QNTM is 5.600
    When was QNTM last traded?
    The last trade of QNTM was at 06/25/26 12:36 PM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.